When to stop: Transfusions, difficult conversations and creativity

IF 7.6 2区 医学 Q1 HEMATOLOGY HemaSphere Pub Date : 2024-05-28 DOI:10.1002/hem3.79
Sophie Evans, Stephen P. Hibbs
{"title":"When to stop: Transfusions, difficult conversations and creativity","authors":"Sophie Evans,&nbsp;Stephen P. Hibbs","doi":"10.1002/hem3.79","DOIUrl":null,"url":null,"abstract":"<p>When working within a haematology day unit I met patients receiving regular blood products as part of a ‘best supportive care’ approach. For some, this was because their disease had not responded to rounds of treatment; others had comorbidities or frailty that made chemotherapy inappropriate. I was often presented with a stack of blood product prescription charts to fill in for the following day. Often I had never met the patients in question, and sometimes there was no documentation about their transfusion regime, or most importantly about the aims of transfusion. For some patients having best supportive care for conditions like myelodysplastic syndrome, myelofibrosis, or aplastic anaemia, there are no prescribing guidelines, and the goal of treatment may never have been discussed. The easiest thing, especially when I was multitasking and under pressure to make quick decisions, was to repeat the previous prescription.</p><p>But as I got to know particular individuals, questions began to arise in my mind. An elderly patient called Bill* had been attending the day unit every 2 weeks for blood transfusions to relieve symptoms of anaemia, caused by myelodysplastic syndrome. Bill had tried oral chemotherapy but had suffered severe infections requiring hospitalisation as a result, and so his treatment had been stopped. Initially, his fatigue and breathlessness were managed well with transfusions every month, but within 6 months, he found the symptom relief would wane after just a week, leaving him lethargic. Accumulation of excess iron from blood transfusions added to his symptom burden. He went from walking into the day unit looking upbeat to being wheeled in looking withdrawn. I started to wonder whether his treatment made him feel better. How could we measure this? Was it right to keep giving him blood transfusions if they didn't help him feel better?</p><p>Since medical school, I have used art and comics to reflect. I have been drawn to patient stories in the realm of graphic medicine, using art and cartoons to explore illness and health narratives. These visual representations are unique reflections in that they allow me to view the artist's perspective in a way that prose does not. Creating something like a comic also allows me time to order my thoughts, to orient and contextualise experiences, and to assign meaning to them. Below is a depiction of an interaction I had with Bill**:</p><p></p><p></p><p></p><p>When I revisit and reflect on this comic, I am clear that Bill needed the time and space to explore his feelings and motivations for treatment. My suggestion of a simple binary choice—to stop or to continue transfusions—looked immature and ill-considered when Bill opened up to me. Without knowing ‘the right thing' to say I chose to sit with him until my pager inevitably went off. I felt that I let him down by not giving him an answer or a plan. Bill had clearly expressed his misery in the hours spent at the day unit, but did I have the right to suggest that he stop attending?</p><p>For many of the other patients on the day unit, the horizon they look to is either cure or death—and this uncertainty brings its own challenges. But for patients like Bill, their outlook is between death or ‘artificially sustained life’. In a group of dialysis-dependent patients interviewed about their quality of life, themes of reflection included the loss of meaningful time to the burden of dialysis treatment, the inability to process the end of life while still receiving treatment, and, surprisingly, a feeling that they had not chosen to start dialysis even though they may have attended preparatory consultations about it.<span><sup>1</sup></span> On this last point, the patients felt they were choosing life as opposed to choosing dialysis. As a doctor, I must be aware of the impact that these intertwined decisions have on a patient giving informed consent. Over time, patients' direct experience allows them to understand more about the treatment decisions they made prior to commencing. Revisiting what treatment means for them provides a space to decide if they wish to continue.</p><p>Discussing treatments and medical conditions can feel abstract. I invited patients to the day unit to try a short creative writing exercise. I gave out a writing prompt of ‘What have you learned from living with your condition?’. Several anonymous responses were returned to the adapted shoebox I left on the reception desk. I was touched to hear from the nurses that some patients had kept their writing to themselves.</p><p>A range of accounts were included in the responses, from a young adult who felt restricted by their condition and physical ability compared to their peers, to an older patient who had received several unusual diagnoses since childhood and had assimilated hospital care into their routine. An elderly patient claimed their condition ‘was not the first thing [I] think about on waking up in the morning’. It struck me that there seemed to be an adjustment in patient narrative over time living with their conditions. This adjustment was not a passive process. The act of reflection and of finding meaning in change can help individuals to shape their stories. Clinicians can create space for patients through direct discussion as well as creative means such as suggesting keeping a diary, writing poetry, or drawing.</p><p>The decision of when to stop is not mine to make. Further clinical evidence might give patients more information about their options, but will not give an ‘answer’ either. By giving permission to patients like Bill to discuss these decisions with trusted clinicians, we challenge the implicit message that treatment must continue and that they must be booked for their next transfusion at the end of each appointment. I wonder if opportunities to let patients explore and shape their illness stories might help them find a way through when treatments are limited and evidence is lacking.</p><p>Both authors conceptualised the article. Sophie Evans wrote the initial draft and authored the figures. Stephen P. Hibbs critically reviewed the article and revised it. All authors agreed to the final version.</p><p>The authors declare no conflict of interest.</p><p>SPH is supported by a HARP doctoral research fellowship, funded by the Wellcome Trust (Grant number 223500/Z/21/Z). No funding was received for this publication.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 5","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11130759/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HemaSphere","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hem3.79","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

When working within a haematology day unit I met patients receiving regular blood products as part of a ‘best supportive care’ approach. For some, this was because their disease had not responded to rounds of treatment; others had comorbidities or frailty that made chemotherapy inappropriate. I was often presented with a stack of blood product prescription charts to fill in for the following day. Often I had never met the patients in question, and sometimes there was no documentation about their transfusion regime, or most importantly about the aims of transfusion. For some patients having best supportive care for conditions like myelodysplastic syndrome, myelofibrosis, or aplastic anaemia, there are no prescribing guidelines, and the goal of treatment may never have been discussed. The easiest thing, especially when I was multitasking and under pressure to make quick decisions, was to repeat the previous prescription.

But as I got to know particular individuals, questions began to arise in my mind. An elderly patient called Bill* had been attending the day unit every 2 weeks for blood transfusions to relieve symptoms of anaemia, caused by myelodysplastic syndrome. Bill had tried oral chemotherapy but had suffered severe infections requiring hospitalisation as a result, and so his treatment had been stopped. Initially, his fatigue and breathlessness were managed well with transfusions every month, but within 6 months, he found the symptom relief would wane after just a week, leaving him lethargic. Accumulation of excess iron from blood transfusions added to his symptom burden. He went from walking into the day unit looking upbeat to being wheeled in looking withdrawn. I started to wonder whether his treatment made him feel better. How could we measure this? Was it right to keep giving him blood transfusions if they didn't help him feel better?

Since medical school, I have used art and comics to reflect. I have been drawn to patient stories in the realm of graphic medicine, using art and cartoons to explore illness and health narratives. These visual representations are unique reflections in that they allow me to view the artist's perspective in a way that prose does not. Creating something like a comic also allows me time to order my thoughts, to orient and contextualise experiences, and to assign meaning to them. Below is a depiction of an interaction I had with Bill**:

When I revisit and reflect on this comic, I am clear that Bill needed the time and space to explore his feelings and motivations for treatment. My suggestion of a simple binary choice—to stop or to continue transfusions—looked immature and ill-considered when Bill opened up to me. Without knowing ‘the right thing' to say I chose to sit with him until my pager inevitably went off. I felt that I let him down by not giving him an answer or a plan. Bill had clearly expressed his misery in the hours spent at the day unit, but did I have the right to suggest that he stop attending?

For many of the other patients on the day unit, the horizon they look to is either cure or death—and this uncertainty brings its own challenges. But for patients like Bill, their outlook is between death or ‘artificially sustained life’. In a group of dialysis-dependent patients interviewed about their quality of life, themes of reflection included the loss of meaningful time to the burden of dialysis treatment, the inability to process the end of life while still receiving treatment, and, surprisingly, a feeling that they had not chosen to start dialysis even though they may have attended preparatory consultations about it.1 On this last point, the patients felt they were choosing life as opposed to choosing dialysis. As a doctor, I must be aware of the impact that these intertwined decisions have on a patient giving informed consent. Over time, patients' direct experience allows them to understand more about the treatment decisions they made prior to commencing. Revisiting what treatment means for them provides a space to decide if they wish to continue.

Discussing treatments and medical conditions can feel abstract. I invited patients to the day unit to try a short creative writing exercise. I gave out a writing prompt of ‘What have you learned from living with your condition?’. Several anonymous responses were returned to the adapted shoebox I left on the reception desk. I was touched to hear from the nurses that some patients had kept their writing to themselves.

A range of accounts were included in the responses, from a young adult who felt restricted by their condition and physical ability compared to their peers, to an older patient who had received several unusual diagnoses since childhood and had assimilated hospital care into their routine. An elderly patient claimed their condition ‘was not the first thing [I] think about on waking up in the morning’. It struck me that there seemed to be an adjustment in patient narrative over time living with their conditions. This adjustment was not a passive process. The act of reflection and of finding meaning in change can help individuals to shape their stories. Clinicians can create space for patients through direct discussion as well as creative means such as suggesting keeping a diary, writing poetry, or drawing.

The decision of when to stop is not mine to make. Further clinical evidence might give patients more information about their options, but will not give an ‘answer’ either. By giving permission to patients like Bill to discuss these decisions with trusted clinicians, we challenge the implicit message that treatment must continue and that they must be booked for their next transfusion at the end of each appointment. I wonder if opportunities to let patients explore and shape their illness stories might help them find a way through when treatments are limited and evidence is lacking.

Both authors conceptualised the article. Sophie Evans wrote the initial draft and authored the figures. Stephen P. Hibbs critically reviewed the article and revised it. All authors agreed to the final version.

The authors declare no conflict of interest.

SPH is supported by a HARP doctoral research fellowship, funded by the Wellcome Trust (Grant number 223500/Z/21/Z). No funding was received for this publication.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
何时停止:输血、艰难的对话和创造力。
这种调整并不是一个被动的过程。反思和在变化中寻找意义的行为可以帮助个人塑造自己的故事。临床医生可以通过直接讨论以及建议写日记、写诗或绘画等创造性方式为患者创造空间。进一步的临床证据可能会为患者提供更多选择信息,但也不会给出'答案'。通过允许像比尔这样的患者与可信赖的临床医生讨论这些决定,我们挑战了 "必须继续治疗 "和 "必须在每次就诊结束后预约下一次输血 "的隐含信息。我在想,当治疗手段有限且缺乏证据时,让患者探索并塑造自己的疾病故事是否能帮助他们找到出路。索菲-埃文斯(Sophie Evans)撰写了文章初稿并绘制了图表。Stephen P. Hibbs对文章进行了严格审阅和修改。所有作者均同意最终版本。作者声明不存在利益冲突。SPH由HARP博士研究奖学金资助,该奖学金由威康信托基金会资助(资助编号为223500/Z/21/Z)。本出版物未获得任何资助。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
HemaSphere
HemaSphere Medicine-Hematology
CiteScore
6.10
自引率
4.50%
发文量
2776
审稿时长
7 weeks
期刊介绍: HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.
期刊最新文献
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA–CAR-T cell therapy: A retrospective study based on LEGEND-2 Monoclonal gammopathy of undetermined significance with multiple paraproteins: A population-based screening study A single-chain variable fragment-based bispecific T-cell activating antibody against CD117 enables T-cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells IL-11—An aging-related cytokine with opportunities for regulating hematopoiesis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1